|
- Ascendis Pharma: Patients. Science. Passion.
Our unwavering focus Ascendis Pharma is a global biopharmaceutical company committed to making a meaningful difference in patients’ lives
- About Us - Ascendis Pharma
Ascendis Pharma was founded in 2007 based on the innovative TransCon technology platform We are headquartered in Copenhagen, Denmark and are publicly traded, following an initial public offering in 2015 (Nasdaq: ASND) We have employees working across the globe to improve patients’ lives
- Pipeline - Ascendis Pharma
Our pipeline of innovative new therapies is driven by the flexibility of our TransCon technologies and our aim to improve patients' lives Ascendis and its partners have multiple prodrug therapies in development Each product candidate is unique and designed to be a best-in-class therapy
- OUR PRODUCTS - Ascendis Pharma
Ascendis Pharma medicines using TransCon technology are authorized for the indications and in the countries or regions shown below Please note that in some countries, a medicine may be authorized for marketing but not yet commercially available
- Contact Us - Ascendis Pharma
Ascendis is headquartered in Denmark and has offices in Germany and in Palo Alto, CA , Princeton, NJ in the U S
- Leadership | Ascendis Pharma
He currently serves on the boards of Ascendis Pharma A S (NASDAQ: ASND) and KalVista Pharmaceuticals (NASDAQ: KALV), and has previously served on the boards of Aclaris Therapeutics (NASDAQ: ACRS), Biohaven Pharmaceuticals (NYSE: BHVN), and many other private and public biopharmaceutical companies
- Careers | Ascendis Pharma
As Ascendis grows, we are always looking to connect with individuals who are passionate about making a meaningful difference for patients If you don’t see an open role that fits your skills and would like to be considered for future opportunities, we encourage you to upload your resume to our country-specific talent pools listed here:
- Endocrinology | Ascendis Pharma
Consistent with our strategic roadmap for growth, we plan to further grow these candidates through label expansion and global clinical reach, either directly or through partnerships Our science aims to make a difference for patients, caregivers, and healthcare providers as we build a potentially best-in-class endocrinology rare disease portfolio
|
|
|